$511 Million is the total value of VR Adviser, LLC's 22 reported holdings in Q3 2020. The portfolio turnover from Q2 2020 to Q3 2020 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CNST | CONSTELLATION PHARMACEUTICAL | $81,382,000 | -32.6% | 4,016,873 | 0.0% | 15.92% | -44.9% | |
| ALT | ALTIMMUNE INC | $59,400,000 | +23.2% | 4,500,000 | 0.0% | 11.62% | +0.7% | |
| SURF | SURFACE ONCOLOGY INC | $26,757,000 | +5.2% | 3,877,895 | 0.0% | 5.23% | -14.1% | |
| KROS | KEROS THERAPEUTICS INC | $25,931,000 | +2.8% | 672,306 | 0.0% | 5.07% | -16.0% | |
| RLMD | RELMADA THERAPEUTICS INC | $25,147,000 | -15.9% | 668,440 | 0.0% | 4.92% | -31.3% | |
| KURA | KURA ONCOLOGY INC | $17,618,000 | +88.0% | 575,000 | 0.0% | 3.45% | +53.6% | |
| SNDX | SYNDAX PHARMACEUTICALS INC | $9,235,000 | -0.4% | 625,710 | 0.0% | 1.81% | -18.6% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-11-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ACLARIS THERAPEUTICS INC | 12 | Q3 2023 | 12.7% |
| VIRIDIAN THERAPEUTICS INC | 12 | Q3 2023 | 13.4% |
| COGENT BIOSCIENCES INC | 12 | Q3 2023 | 10.3% |
| RELMADA THERAPEUTICS INC | 11 | Q3 2022 | 9.9% |
| GH RESEARCH PLC | 10 | Q3 2023 | 6.7% |
| ALTIMMUNE INC | 9 | Q3 2022 | 11.6% |
| MARINUS PHARMACEUTICALS INC | 9 | Q4 2022 | 5.7% |
| CELLDEX THERAPEUTICS INC | 9 | Q3 2022 | 7.6% |
| AFFIMED N V | 8 | Q3 2023 | 1.1% |
| INSTIL BIO INC | 7 | Q3 2022 | 18.7% |
View VR Adviser, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-11 |
| 13F-HR/A | 2023-05-15 |
| 13F-HR/A | 2023-05-15 |
| 13F-HR/A | 2023-05-15 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
View VR Adviser, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.